Treatment group:CAR-T cell infusion therapy

3 trials

Sponsors

Chinese People's Liberation Army (PLA) General Hospital, The Second People's Hospital of Nanyang

Conditions

CD19-positive hematological malignanciesRefractory and relapsed multiple myeloma

Early Phase 1

A single-arm clinical study of PD-1Ab21-CD19CAR-T cells (PZ04) in the treatment of CD19-positive hematological malignancies

RecruitingChiCTR2300072572

Chinese People's Liberation Army (PLA) General HospitalCD19-positive hematological malignancies

Start: 2022-08-01Updated: 2023-06-18

A single-arm clinical study of PD-1Ab21-CD19CAR-T cells in the treatment of CD19-positive hematological malignancies

RecruitingChiCTR2300077759

The Second People's Hospital of NanyangCD19-positive hematological malignancies

Start: 2023-05-15Updated: 2023-11-21

Single-arm clinical study of PD-1Ab21-BCMACAR-T cells (CD003) in the treatment of refractory and relapsed multiple myeloma

RecruitingChiCTR2300078977

Chinese People's Liberation Army (PLA) General HospitalRefractory and relapsed multiple myeloma

Start: 2023-05-23Updated: 2024-01-08